Strontium as therapy for osteoporosis.

Curr Opin Pharmacol

INSERM U606 and University Paris 7, Lariboisière Hospital, 2 Rue Ambroise Paré, 75475 Paris cedex 10, France.

Published: December 2005

Osteoporosis is characterized by low bone mass and increased susceptibility to fracture. Recent in vitro studies showed that strontium ranelate, a novel agent containing two strontium atoms, acts as an effective anti-osteoporotic drug by inhibiting bone resorption by osteoclasts and promoting osteoblast replication and bone formation. Studies in animals demonstrated that strontium ranelate increases bone mass, microarchitecture and strength in intact rodents and prevents bone loss in osteopenic animals. Clinical studies show that strontium ranelate reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporosis. Together, these recent advances point to unique effects of strontium ranelate on bone cells and show that strontium ranelate has significant clinical benefits in the treatment of postmenopausal osteoporosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2005.05.005DOI Listing

Publication Analysis

Top Keywords

strontium ranelate
20
bone mass
8
studies strontium
8
postmenopausal osteoporosis
8
strontium
7
bone
6
ranelate
5
strontium therapy
4
osteoporosis
4
therapy osteoporosis
4

Similar Publications

Article Synopsis
  • Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition impacting women postpartum, exemplified by a case of a 29-year-old with severe back pain due to vertebral fractures.
  • Diagnosis involves ruling out other causes of osteoporosis, with treatment typically including calcium and vitamin D supplements alongside lactation suppression; however, pain may persist even after treatment.
  • The condition remains poorly understood, with potential causes including genetic factors and calcium metabolism changes, highlighting the need for early diagnosis and personalized treatment strategies for better patient outcomes.
View Article and Find Full Text PDF

Repairing effect of magnesium oxychloride cement modified by γ-polyglutamic acid and chitosan in osteoporotic bone defect.

Int J Biol Macromol

December 2024

Henan Key Laboratory of Materials on Deep-Earth Engineering, School of Materials Science and Engineering, Henan Polytechnic University, Jiaozuo, China. Electronic address:

Magnesium oxychloride cement (MOC) has the advantage of high early strength. However, it has the defect of poor water resistance. Considering this performance, we use γ-polyglutamic acid (γ-PGA) and chitosan (CS) to modify MOC.

View Article and Find Full Text PDF

Multiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab.

Bone

January 2025

Pharmacoepidemiology and Pharmacovigilance Department, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain. Electronic address:

Article Synopsis
  • Discontinuation of anti-osteoporotic medications, particularly Prolia® (denosumab), significantly increases the risk of multiple vertebral fractures (MVF) due to a rapid rise in bone turnover markers and loss of bone mineral density.
  • A study using data from the Public Health System in Spain analyzed patients who had recently started various anti-osteoporotic medications, finding a strong association between denosumab discontinuation and a 2.82 times higher risk of MVF compared to those still on the medication.
  • The risk of MVF after stopping denosumab was especially high within the first 3 to 9 months after discontinuation, increasing further after longer cumulative use of
View Article and Find Full Text PDF

Osteoarthritis year in review 2024: Imaging.

Osteoarthritis Cartilage

January 2025

Department of Radiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA; Department of Radiology, Boston VA Healthcare System, West Roxbury, MA, USA.

Objective: To review recent literature evidence describing imaging of osteoarthritis (OA) and to identify the current trends in research on OA imaging.

Method: This is a narrative review of publications in English, published between April, 2023, and March, 2024. A Pubmed search was conducted using the following search terms: osteoarthritis/OA, radiography, ultrasound/US, computed tomography/CT, magnetic resonance imaging/MRI, DXA/DEXA, and artificial intelligence/AI/deep learning.

View Article and Find Full Text PDF

Alleviating rheumatoid arthritis with a photo-pharmacotherapeutic glycan-integrated nanogel complex for advanced percutaneous delivery.

J Nanobiotechnology

October 2024

Graduate Institute of Biomedical Materials and Tissue Engineering, Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, New Taipei City, Taiwan.

The prospective of percutaneous drug delivery (PDD) mechanisms to address the limitations of oral and injectable treatment for rheumatoid arthritis (RA) is increasing. These limitations encompass inadequate compliance among patients and acute gastrointestinal side effects. However, the skin's intrinsic layer can frequently hinder the percutaneous dispersion of RA medications, thus mitigating the efficiency of drug delivery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!